AHA 2022: Bivalirudin With a Post-PCI High-Dose Infusion versus Heparin Monotherapy During Primary PCI in STEMI - The Randomized BRIGHT-4 Trial
By
AHA 2022 Conference Coverage
FEATURING
Gregg W. Stone
November 14, 2022
Login to view comments.
Click here to Login